Drugs / KM602
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05766527 | Apr 2023 → Dec 2025 overdue | neoplasm | Xuanzhu Biopharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KM602 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05766527 ↗ |
| Route | Intravenous | “KM602 is administered intravenously once a week” NCT05766527 ↗ |